Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
RBC Capital analyst Brian Abrahams maintains Pliant Therapeutics (NASDAQ:PLRX) with a Sector Perform and lowers the price ta...
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $...
JP Morgan analyst Brian Cheng downgrades Pliant Therapeutics (NASDAQ:PLRX) from Neutral to Underweight.
Piper Sandler analyst Yasmeen Rahimi maintains Pliant Therapeutics (NASDAQ:PLRX) with a Overweight and lowers the price targ...
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.71) per share which met the analyst consensus estimate. This...
Bexotegrast development in IPF discontinuedClinical oncology program and early-stage programs continueRecent workforce and oper...
Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company led oral and poster presentations of clinical and prec...
Pliant Therapeutics (NASDAQ:PLRX) reported quarterly losses of $(0.92) per share which missed the analyst consensus estimate of...
